NeoGenesis Pens Drug Discovery Deal with Mitsubishi-Tokyo | GenomeWeb

NEW YORK, Aug 16 – NeoGenesis Drug Discovery has announced a deal to work with Mitsubishi-Tokyo Pharmaceuticals to identify small-molecule drug candidates. 

Under the terms of the deal, NeoGenesis of Cambridge, Mass., will use its genomics technologies to identify proteins that can be used as therapeutics. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.